Photodynamic and Pharmacologic Treatment of CNV

Summary

The goal of this pilot study is to validate the use of the combination of Lucentis (ranibizumab) and Visudyne (verteporfin) in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and to explore the use of a volumetric analysis of the CNV lesion to determine disease activity, response to therapy, and as a tool for determining the need for retreatment.

Timeline

Start

2006-12

Primary completion

2011-06

Completion

2011-06

Drugs

Indications